PT1824504E - Combinações antitumorais contendo vegf-trap e 5fu ou um de seus derivados - Google Patents

Combinações antitumorais contendo vegf-trap e 5fu ou um de seus derivados Download PDF

Info

Publication number
PT1824504E
PT1824504E PT05824581T PT05824581T PT1824504E PT 1824504 E PT1824504 E PT 1824504E PT 05824581 T PT05824581 T PT 05824581T PT 05824581 T PT05824581 T PT 05824581T PT 1824504 E PT1824504 E PT 1824504E
Authority
PT
Portugal
Prior art keywords
trap
derivatives
combinations containing
containing vegf
antitumor combinations
Prior art date
Application number
PT05824581T
Other languages
English (en)
Inventor
Marie-Christine Bissery
Patricia Vrignaud
Marielle Chiron-Blondel
Eric Furfine
Jocelyn Holash
Jesse M Cedarbaum
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34954452&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1824504(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of PT1824504E publication Critical patent/PT1824504E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT05824581T 2004-12-03 2005-12-02 Combinações antitumorais contendo vegf-trap e 5fu ou um de seus derivados PT1824504E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0412870A FR2878749B1 (fr) 2004-12-03 2004-12-03 Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives

Publications (1)

Publication Number Publication Date
PT1824504E true PT1824504E (pt) 2009-06-25

Family

ID=34954452

Family Applications (1)

Application Number Title Priority Date Filing Date
PT05824581T PT1824504E (pt) 2004-12-03 2005-12-02 Combinações antitumorais contendo vegf-trap e 5fu ou um de seus derivados

Country Status (26)

Country Link
US (3) US20060178305A1 (pt)
EP (1) EP1824504B1 (pt)
JP (1) JP4980236B2 (pt)
KR (1) KR101313404B1 (pt)
CN (1) CN101068564B (pt)
AT (1) ATE426409T1 (pt)
AU (1) AU2005311191C1 (pt)
BR (1) BRPI0518700B8 (pt)
CA (1) CA2586735C (pt)
CY (3) CY1109181T1 (pt)
DE (1) DE602005013568D1 (pt)
DK (1) DK1824504T3 (pt)
ES (1) ES2324233T3 (pt)
FR (1) FR2878749B1 (pt)
HK (1) HK1114769A1 (pt)
HR (1) HRP20090336T1 (pt)
IL (1) IL183481A (pt)
LU (2) LU92203I2 (pt)
ME (1) ME01706B (pt)
MX (1) MX2007006607A (pt)
PL (1) PL1824504T3 (pt)
PT (1) PT1824504E (pt)
RS (1) RS50769B (pt)
RU (1) RU2384344C2 (pt)
SI (1) SI1824504T1 (pt)
WO (1) WO2006059012A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
JO3283B1 (ar) * 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EA035674B1 (ru) 2014-07-18 2020-07-24 Санофи Способ определения того, является ли пациент, предположительно страдающий от рака, кандидатом для терапии афлиберцептом
CA3010056A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
EP3246029A1 (en) * 2016-05-19 2017-11-22 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
CN115197948A (zh) * 2021-04-13 2022-10-18 江苏康缘瑞翱生物医药科技有限公司 一种重组新城疫病毒rNDV-VEGF-Trap、其基因组、制备方法及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
ATE293164T1 (de) * 1999-06-08 2005-04-15 Regeneron Pharma Modifizierte chimärische polypeptide mit verbesserten pharmakokynetischen eigenschaften
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo

Also Published As

Publication number Publication date
CN101068564B (zh) 2010-12-15
AU2005311191A1 (en) 2006-06-08
US8388963B2 (en) 2013-03-05
CA2586735A1 (fr) 2006-06-08
LU92203I9 (pt) 2019-01-15
CA2586735C (fr) 2014-08-12
EP1824504B1 (fr) 2009-03-25
KR101313404B1 (ko) 2013-10-01
CY2013018I1 (el) 2020-05-29
BRPI0518700B8 (pt) 2021-05-25
LU92203I2 (fr) 2013-11-15
FR2878749B1 (fr) 2007-12-21
RU2384344C2 (ru) 2010-03-20
RS50769B (sr) 2010-08-31
CY1109181T1 (el) 2014-07-02
CY2013017I1 (el) 2014-07-02
FR2878749A1 (fr) 2006-06-09
EP1824504A1 (fr) 2007-08-29
JP4980236B2 (ja) 2012-07-18
CN101068564A (zh) 2007-11-07
KR20070091130A (ko) 2007-09-07
ATE426409T1 (de) 2009-04-15
DK1824504T3 (da) 2009-07-20
DE602005013568D1 (de) 2009-05-07
WO2006059012A1 (fr) 2006-06-08
LU92202I9 (pt) 2019-01-15
MX2007006607A (es) 2007-07-25
PL1824504T3 (pl) 2009-08-31
IL183481A (en) 2013-09-30
AU2005311191B2 (en) 2011-12-08
HRP20090336T1 (en) 2009-07-31
AU2005311191C1 (en) 2015-04-30
IL183481A0 (en) 2007-09-20
ES2324233T3 (es) 2009-08-03
BRPI0518700A2 (pt) 2008-12-02
HK1114769A1 (en) 2008-11-14
JP2008521866A (ja) 2008-06-26
US20130184205A1 (en) 2013-07-18
LU92202I2 (fr) 2013-11-15
RU2007123607A (ru) 2009-01-10
US20090285841A1 (en) 2009-11-19
ME01706B (me) 2010-08-31
US20060178305A1 (en) 2006-08-10
BRPI0518700B1 (pt) 2020-02-11
SI1824504T1 (sl) 2009-08-31

Similar Documents

Publication Publication Date Title
LU92203I9 (pt)
GEP20125691B (en) Compounds and compositions as protein kinase inhibitors
CY1116156T1 (el) Παραγωγα πυριμιδινης συνδεδεμενα με οξυγονο
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
MY143407A (en) Indazole derivatives as inhibitors of hormone sensitive lipase
NO20065368L (no) Terapeutiske blandinger inneholdende minst et pyrrolobenzodiazepinderivat og fludarabin
TW200728285A (en) Diacylindazole derivatives as inhibitors of lipases and phospholipases
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
GB0226434D0 (en) Combination product
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
CY1111762T1 (el) Διενυδρη παμοϊκη ολανζαπiνη
EA200970353A1 (ru) Комбинированное лекарственное средство
TW200716561A (en) P38 inhibitors and methods of use thereof
WO2006128740A3 (en) Anti-vascular methods and therapies employing lysyl oxidase inhibitors
SE0300457D0 (sv) Novel compounds
EA200971103A1 (ru) Иммуноцитокины для лечения рака в сочетании с химиотерапевтическими агентами
BRPI0507985A (pt) derivados de piperazina uréia para o tratamento de endometriose
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
WO2007012967A3 (en) Combination of voriconazole and fluconazole
BRPI0419229A (pt) derivados de tiofenopirimidinona substituìdos como inibidores de 17beta-hidroxiesteróide-desidrogenase, uso e composição farmacêutica
UA95260C2 (ru) Производное 4-(3-аминопиразол)пиримидина и его применение для лечения злокачественного новообразования